Lung cancer remains one of the most challenging tasks in modern oncology — and it is in this area that the Ichilov (Sourasky) Medical Center in Tel Aviv has accumulated one of the strongest profiles in Israel. The thoracic surgery department, the Institute of Oncology, and the Institute of Lung Diseases work as a unified team: each case is discussed at an interdisciplinary Tumor Board before treatment begins, ensuring that the protocol is tailored to the specific tumor rather than an average "standard."
Diagnosis starts with a targeted algorithm — low-dose chest CT, PET-CT, endobronchial ultrasound (EBUS) with transbronchial biopsy, molecular tumor analysis for EGFR, ALK, ROS1, KRAS, BRAF, and PD-L1 expression assessment. The results determine the entire pathway: for early-stage disease — radical VATS lobectomy or robotic resection through several millimeter ports instead of open thoracotomy; for locally advanced forms — concurrent chemoradiotherapy followed by durvalumab immunotherapy; for stage IV — targeted therapies or checkpoint inhibitors tailored to the molecular profile.
This subsection contains materials on key histological types of the disease: lung adenocarcinoma, squamous cell carcinoma, lung sarcoma, bronchial cancer, rare BALT lymphoma, and tumors of adjacent structures. Separate articles are dedicated to diagnostic methods — from blood tests for tumor markers and PET-CT to pulmonary vessel angiography — and surgical technologies employed by the thoracic surgery department at Sourasky.
Below are articles, diagnostic programs, and specialist doctors at the clinic: thoracic surgeons, oncologists-chemotherapists, and pulmonologists who lead international patients. If you would like to get a second opinion on your case, assess the possibility of surgery, or select a protocol for targeted/immunotherapy, please leave a request — the coordinator of the international department at Ichilov will contact you within the working day and arrange a consultation with a specialist.